1. Home
  2. HRMY vs SUPN Comparison

HRMY vs SUPN Comparison

Compare HRMY & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$38.97

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$47.49

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
SUPN
Founded
2017
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.6B
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
HRMY
SUPN
Price
$38.97
$47.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
4
Target Price
$51.33
$63.25
AVG Volume (30 Days)
789.9K
664.8K
Earning Date
11-04-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
50.44
N/A
EPS
3.17
N/A
Revenue
$825,944,000.00
$681,539,000.00
Revenue This Year
$23.11
$8.32
Revenue Next Year
$16.15
$23.36
P/E Ratio
$12.79
N/A
Revenue Growth
21.13
4.54
52 Week Low
$25.52
$29.16
52 Week High
$40.93
$57.65

Technical Indicators

Market Signals
Indicator
HRMY
SUPN
Relative Strength Index (RSI) 67.08 54.34
Support Level $38.12 $45.36
Resistance Level $40.00 $47.26
Average True Range (ATR) 1.26 1.23
MACD 0.13 0.40
Stochastic Oscillator 68.68 91.91

Price Performance

Historical Comparison
HRMY
SUPN

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: